Physician profile
Abel A Gonzalez
NPI 1962445940
$74,077.65
in general payments reported to CMS, 2019-2025
34 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $599 · 2021: $2,638 · 2022: $5,715 · 2023: $14K · 2024: $32K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Honoraria: $13K · Travel and Lodging: $6,806 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,600.00 |
| Food and Beverage | $15,098.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,780.00 |
| Honoraria | $12,725.00 |
| Travel and Lodging | $6,805.92 |
| Education | $283.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28,521.10 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $22,097.57 | 2021-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $4,719.82 | 2022-2025 | Quviviq, Quviviq |
| Abbvie INC. | $2,198.78 | 2021-2025 | |
| Alkermes, INC. | $1,903.13 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,893.27 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $1,417.32 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,272.93 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $1,018.86 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $894.83 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $894.15 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $861.08 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $719.22 | 2019-2025 | Invega Sustenna |
| Harmony Biosciences LLC | $682.15 | 2022-2025 | Wakix |
| Tris Pharma INC | $588.65 | 2022-2025 | Dyanavel Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $545.28 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $538.93 | 2019-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $511.82 | 2019-2025 | |
| Corium, LLC | $447.93 | 2022-2025 | Azstarys |
| Allergan, INC. | $417.64 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $415.47 | 2019-2023 | Belsomra |
| Bausch Health US, LLC | $369.45 | 2020-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $301.85 | 2021-2023 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $284.83 | 2025 | Jornay Pm |
| Eisai INC. | $141.16 | 2021-2022 | |
| Almatica Pharma LLC | $75.58 | 2024-2025 | Loreev Xr |
| Alfasigma USA, INC. | $72.65 | 2021-2022 | |
| Shire North American Group INC | $68.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $52.56 | 2024-2025 | Relexxii |
| Astellas Pharma US INC | $51.72 | 2024-2025 | Veozah, Cresemba |
| Sunovion Pharmaceuticals INC. | $50.91 | 2021 | |
| Adlon Therapeutics L.P. | $17.17 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.21 | 2020 | |
| Boston Scientific Corporation | $15.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.